Traws Pharma, Inc.
TRAW · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $9 | $9 | $9 | $16 |
| - Cash | $13 | $21 | $17 | $21 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$4 | -$13 | -$8 | -$5 |
| Revenue | $3 | $0 | $0 | $0 |
| % Growth | 4,694.7% | 1.8% | -50.4% | – |
| Gross Profit | $3 | $0 | $0 | $0 |
| % Margin | 100% | 96.5% | 100% | 96.5% |
| EBITDA | -$2 | -$8 | -$5 | -$9 |
| % Margin | -91.3% | -14,864.9% | -9,300% | -8,198.2% |
| Net Income | -$1 | -$8 | -$5 | -$9 |
| % Margin | -22.9% | -14,868.4% | -8,898.2% | -7,896.5% |
| EPS Diluted | -0.11 | -8.81 | -5.92 | -10.621 |
| % Growth | 98.8% | -48.8% | 44.3% | – |
| Operating Cash Flow | -$6 | -$4 | -$10 | -$4 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$6 | -$4 | -$10 | -$4 |